Etid klinik pou Kansè ovè nan Arizona
26 etid pou Kansè ovè ap chèche patisipan nan sit nan Arizona.
Vil nan Arizona
Tèks ofisyèl etid la (Anglè)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- CTCA at Western Regional Medical Center, Goodyear
- Kingman Regional Medical Center, Kingman
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT05564377A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Gilbert
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0143 - HonorHealth, Phoenix
- Site 0102 - University of Arizona Cancer Center, Tucson
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05128825Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Mayo Clinic, Phoenix
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05051722DESTINY-PANTUMOUR04
- Research Site, Bullhead City
- Research Site, Casa Grande
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Banner Health, Gilbert
- Mayo Clinic Hospital, Phoenix
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- HonorHealth, Phoenix
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213804Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- University of Arizona Cancer Center, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT07214779ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Ironwood Cancer & Research Centers, Chandler
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- HonorHealth, Scottsdale
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- University of Arizona Cancer Center, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Aug 26, 2026 · NCT05281471A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0107, Phoenix
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Aug 12, 2026 · NCT07546500A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
Ap rekrite
Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Cancer Center at Saint Joseph's, Phoenix
- Mayo Clinic Hospital in Arizona, Phoenix
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR HonorHealth, Phoenix
- USOR Arizona Oncology Associates, Tucson
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Mayo Clinic (Arizona), Scottsdale
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068AOH1996 for the Treatment of Refractory Solid Tumors
- Honor Health Research and Innovation Institute, Scottsdale
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT05227326Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #108, Goodyear
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 23, 2026 · NCT06545942Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
- Mayo Clinic Arizona, Phoenix
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 14, 2026 · NCT05804370A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Mayo Clinic Comprehensive Cancer Center, Phoenix
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Banner Health, Gilbert
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT06051695A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Mayo Clinic, Phoenix
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT06395519MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
- Mayo Clinic in Arizona, Scottsdale
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Mar 16, 2026 · NCT06483048A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- HonorHealth Research Institute, Scottsdale
- The University of Arizona Cancer Center, Tucson
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT06778863CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Mayo Clinic Hospital, Phoenix
- SCRI - Arizona Oncology Associates, PC-HOPE, Tucson
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Dec 23, 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scottsdale
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.